23 stories found
Pharmaceutical giant AbbVie has finalized its $11 billion purchase of biotechnology company Apogee Therapeutics, expanding its oncology pipeline. The deal marks one of the largest recent acquisitions in the life sciences sector.
Apogee Therapeutics has released its financial results for the second quarter of the year.
Pharmaceutical giant AbbVie (ABBV) has revealed its plans to acquire Apogee Therapeutics, a move expected to expand its portfolio and market presence.
AbbVie has announced its acquisition of Apogee Therapeutics for $10.9 billion in cash, aiming to bolster its immunology pipeline with next-generation inflammatory disease drugs. The deal caused Apogee's stock to surge significantly.
Apogee Therapeutics has successfully arranged $1.3 billion in strategic financing to advance its zumilokibart drug development program.
A range of companies across various sectors, including Constellation Energy, Liquidia, and Cineplex, have released their first-quarter financial results. These reports show a mix of performances, with some firms exceeding and others falling short of analyst expectations.
Apogee Therapeutics has announced a public offering aimed at raising $300 million.
Apogee Therapeutics has released its full-year financial results.
Shares of the biotechnology company reached a record price of $134.89 following positive market developments.
Baron Capital has divested its holdings in Apogee Therapeutics (APGE) after the company was acquired by AbbVie.
Apogee Therapeutics (APGE) shares reached a fresh high following the announcement of a $10.9 billion merger with AbbVie, signaling a major acquisition in the pharmaceutical industry.
AbbVie is reportedly close to acquiring Apogee Therapeutics in a deal valued at $10.9 billion, which would provide AbbVie with an experimental eczema drug.
Apogee Therapeutics shares fell following the announcement of phase 2 clinical trial results for its drug zumilokibart, intended for the treatment of atopic dermatitis.
Apogee Therapeutics Inc. (APGE) is highlighted as a primary challenger to established blockbuster drugs in the pharmaceutical market.
Apogee Therapeutics shares have increased following positive phase 2 clinical trial results for its drug Zumilokibart, intended for atopic dermatitis treatment.
This cluster includes news on analyst ratings, significant investment filings, regulatory compliance, proposed rights issues, and new business orders for individual companies.
Several company directors have engaged in stock transactions, with some purchasing shares and others selling. These activities include a director buying $49,272 in electroCore stock and another selling $274,938 in Hanover Insurance Group common stock.
AbbVie Inc. is looking to raise at least $8 billion through an investment-grade bond offering to finance a portion of its acquisition of Apogee Therapeutics Inc. This debt issuance will support the significant corporate transaction.
Several stocks, including Alphabet, AeroVironment, Salesforce, Apogee Therapeutics, SpaceX, and Arcosa, experienced significant movement in both premarket and midday trading. These companies were highlighted for their notable gains or losses during the trading sessions.
Reports indicate that pharmaceutical giant AbbVie is close to finalizing an $11 billion deal to acquire Apogee Therapeutics, a biotechnology company.
Apogee Therapeutics (APOG) shares have surged after the company announced a $1.3 billion financing partnership with Blackstone, boosting investor confidence.
Apogee Therapeutics has priced an upsized public offering of $350 million, with shares offered at $70 each.
Telsey Advisory has raised its price target for Costco Wholesale Corporation (COST) from $1,100 to $1,125.